Newark, Delaware 19713


The purpose of this study is to examine the effect of mitochondria derived oxidative stress on vascular function in patients with moderate to severe Chronic Kidney Disease.

Study summary:

Chronic Kidney Disease (CKD) patients are at increased risk of cardiovascular disease. Endothelial dysfunction, characterized by a reduced bioavailability in nitric oxide, is an independent predictor of cardiovascular disease in CKD. Increased oxidative stress is a potential cause of endothelial dysfunction in this patient cohort. This study investigates the role that mitochondrial derived oxidative stress plays in CKD related vascular dysfunction. In a controlled, double blinded trial, Stage 3-5 CKD patients will be randomly assigned to receive a 4 week daily dose of a mitochondria targeted antioxidant (MitoQ) or a placebo.


Inclusion Criteria: - Stage 3 - 5 Chronic Kidney Disease Exclusion Criteria: - History of cardiovascular disease; - Current pregnancy; - Uncontrolled hypertension; - Uncontrolled hyperlipidemia; - Current hormone replacement therapy; - Current use of tobacco products; - Elevated liver enzymes; - Current autoimmune disease; - Daily use of of antioxidants >300mg



Primary Contact:

Principal Investigator
Danielle L Kirkman, PhD
University of Delaware

Danielle L Kirkman, PhD
Phone: 302 831 4659

Backup Contact:

David G Edwards, PhD

Location Contact:

Newark, Delaware 19713
United States

David Edwards, PhD

Site Status: Recruiting

Data Source:

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.